Risk factors and consequences of conversion in laparoscopic major liver resection

F. Cauchy^{1,3}, D. Fuks², T. Nomi², L. Schwarz¹, L. Barbier³, S. Dokmak³, O. Scatton¹, J. Belghiti³, O. Soubrane^{1,3} and B. Gayet²

¹Department of Hepatobiliary and Liver Transplantation, Hôpital Saint Antoine, and ²Department of Digestive Disease, Institut Mutualiste Montsouris, Paris, and ³Department of Hepatobiliary and Liver Transplantation, Hôpital Beaujon, Clichy, France

Correspondence to: Dr D. Fuks, Department of Digestive Diseases, Institut Mutualiste Montsouris, 42 Boulevard Jourdan, 75014 Paris, France (e-mail: davidfuks80@gmail.com)

Background: Although recent reports have suggested potential benefits of the laparoscopic approach in patients requiring major hepatectomy, it remains unclear whether conversion to open surgery could offset these advantages. This study aimed to determine the risk factors for and postoperative consequences of conversion in patients undergoing laparoscopic major hepatectomy (LMH).

Methods: Data for all patients undergoing LMH between 2000 and 2013 at two tertiary referral centres were reviewed retrospectively. Risk factors for conversion were determined using multivariable analysis. After propensity score matching, the outcomes of patients who underwent conversion were compared with those of matched patients undergoing laparoscopic hepatectomy who did not have conversion, operated on at the same centres, and also with matched patients operated on at another tertiary centre during the same period by an open laparotomy approach.

Results: Conversion was needed in 30 (13.5 per cent) of the 223 patients undergoing LMH. The most frequent reasons for conversion were bleeding and failure to progress, in 14 (47 per cent) and nine (30 per cent) patients respectively. On multivariable analysis, risk factors for conversion were patient age above 75 years (hazard ratio (HR) 7.72, 95 per cent c.i. 1.67 to 35.70; P = 0.009), diabetes (HR 4.51, 1.16 to 17.57; P = 0.030), body mass index (BMI) above 28 kg/m^2 (HR 6.41, 1.56 to 26.37; P = 0.010), tumour diameter greater than 10 cm (HR 8.91, 1.57 to 50.79; P = 0.014) and biliary reconstruction (HR 13.99, 1.82 to 238.13; P = 0.048). After propensity score matching, the complication rate in patients who had conversion was higher than in patients who did not (75 versus 47.3 per cent respectively; P = 0.038), but was not significantly different from the rate in patients treated by planned laparotomy (79 versus 67.9 per cent respectively; P = 0.438).

Conclusion: Conversion during LMH should be anticipated in patients with raised BMI, large lesions and biliary reconstruction. Conversion does not lead to increased morbidity compared with planned laparotomy.

Paper accepted 12 February 2015 Published online 2 April 2015 in Wiley Online Library (www.bjs.co.uk). **DOI:** 10.1002/bjs.9806

Introduction

Since the first report of a successful laparoscopic liver resection (LLR), diffusion of the laparoscopic approach in liver surgery has been slow because of initial concerns regarding operative risks, oncological issues^{1,2} and technical difficulties. Nevertheless, laparoscopy has now been shown to provide several advantages over laparotomy, including diminished blood loss³, fewer complications⁴⁻⁷ and ascites^{5,6,8}, as well as shorter hospital stays^{9,10}. These benefits are thought to be related to the

pneumoperitoneum, which limits blood loss and may enhance inflow occlusion when prior selective vascular inflow control is performed, but are also related to the absence of a large incision. The smaller incisions allow preservation of collateral abdominal wall vascularization in patients with cirrhosis, diminish postoperative pain and enhance early rehabilitation. In this setting, although conversion to open liver resection would intuitively offset these benefits, its true influence on the postoperative course of patients undergoing LLR is still unanswered. Laparoscopic major hepatectomy (LMH) is currently considered the most challenging LLR procedure. It requires mastery of both laparoscopic pedicular dissection and parenchymal transection of large-sized cut surfaces. Hence it is generally accepted that LMH should be attempted only after considerable expertise in LLR has been acquired¹¹. Still, even in experienced hands, approximately 10–20 per cent of patients undergoing major LLR require conversion to open hepatectomy^{12–15}, whereas standard LLR is associated with conversion rates of less than 5 per cent¹⁶. LMH could represent a relevant model for accurate identification of preoperative risk factors for, and consequences of, conversion in order to improve the perioperative management of these patients.

The present study aimed to determine the risk factors for conversion to open hepatectomy and to analyse the postoperative consequences of conversion in patients undergoing LMH using propensity score matching of patients operated on at three tertiary-referral hepatopancreatobiliary units.

Methods

The study included all patients undergoing fully laparoscopic major (at least 3 contiguous Couinaud segments¹⁷) right or left liver resection at the Institut Mutualiste Montsouris (centre 1) in 2000-2013 and at Hôpital Saint Antoine (centre 2) in 2009-2013, as well as all patients undergoing open major hepatectomy at Hôpital Beaujon (centre 3) in 2000-2013. No patient had a planned hand-assisted or hybrid approach. For centre 2, the first major LLRs were performed in 2007, but relocation of the surgical team to another hospital in 2009 prevented collection of data before 2009. In centre 3 no patient underwent LMH during the study interval. The collected data were retrieved from prospectively maintained databases and included baseline patient characteristics such as demographic data, preoperative risk factors and co-morbidities, type of preoperative management, operative characteristics including intraoperative incidents, pathological data and postoperative outcomes. The study was approved by the local institutional review board at each centre.

Surgical technique

Laparoscopy group

All procedures were performed by at least one senior surgeon. Liver transection was done under low (less than 5 mmHg) central venous pressure¹⁸. Briefly, LMIH was performed using five or six ports depending on the surgical procedure and operator preference, as described previously^{12,19}. Laparoscopic ultrasonography was used routinely to guide the resection. The operative technique was similar to that for open surgery: isolation and division of hepatic inflow, absence of mobilization of the liver before transection, and subsequent transection of liver parenchyma. Clamping of the hepatic inflow pedicle was not performed routinely during this step, and the Pringle manoeuvre was used only when there was bleeding. Energy sources and parenchymal division techniques varied throughout the study period. During the early years, tissue dissection and haemostasis were performed using ultrasonic dissector or scalpel, while bipolar forceps provided retraction and haemostasis. In more recent years, the harmonic scalpel (primarily SonoSurg[®]; Olympus, Tokyo, Japan) and, more recently, Harmonic[®] (Ethicon EndoSurgery, Cincinnati, Ohio, USA) or Thunderbeat® (Olympus, Tokyo, Japan) was frequently used, especially for transection of superficial parenchyma. When parenchymal transection reached the hilar plate, segment I was divided along the right aspect of the inferior vena cava. This step is essential to allow dissection of both the right bile duct and the hilar plate, which were then taped, closed using either a large secured clip or a stapler, and finally cut. At the end of parenchymal transection, the hepatic outflow was divided with an endoscopic vascular stapler. The resected specimen was finally mobilized, placed in a plastic bag and removed, without fragmentation, preferentially through a 5-8-cm suprapubic incision without muscle section. This incision was closed immediately and the abdomen reinsufflated to confirm haemostasis and absence of bile leaks. Methylene blue or air injection through the cystic drain was not performed routinely. Abdominal drainage was used only when there was concern about intraoperative bile control or the adequacy of haemostasis, regardless of the approach.

Selection criteria for the use of the laparoscopic approach evolved over time and varied according to centre, but patients qualified for LMH only when lesions were far from the liver hilum, hepatocaval junction and inferior vena cava. All lesions had to be well clear of the mid-plane of the liver to allow adequate surgical margins. Hence, laparoscopy was contraindicated when total vascular exclusion without or with liver cooling and reconstruction of major vascular structures (portal vein/branch or hepatic vein/inferior vena cava) were required. Although the laparoscopic approach was avoided initially in patients with huge lesions and those requiring biliary reconstruction, these situations did not represent absolute contraindications to the laparoscopic approach in more recent years. Previous abdominal surgery, obesity, underlying cirrhosis, bilobar disease and previous portal vein embolization were not considered contraindications to the laparoscopic approach.

Conversion to open surgery

Conversion was defined as the requirement for laparotomy at any time of the procedure, except extraction of the resected specimen. For the purpose of this study, specific data regarding conversion were retrieved from the operative reports. These included reasons for conversion, and the timing and type of conversion. Reasons for conversion were categorized as: haemorrhage considered difficult to control under laparoscopy, failure to progress, existence of tight adhesions, operative discovery of unexpected tumour spread and operative incident (excluding haemorrhage). Timing of conversion was defined as follows: before pedicular dissection; between pedicular dissection and hilar plate section; and from hilar plate section to the end of the procedure. The types of conversion were categorized as: subcostal incision, J-shaped incision, midline incision and hand port placement. Finally, conversion rates were compared according to the experience of each centre. In this setting, early experience and late experience accounted for the first half and second half respectively of the total number of patients operated on.

Planned laparotomy group

At centre 3, all procedures were performed by at least one senior surgeon. The procedures were carried out through bilateral or J-shaped incision depending on tumour location and surgeon preference. Liver transection was performed under low central venous pressure¹⁸ without prior mobilization, using the hanging manoeuvre in most patients and the crush-clamp technique or ultrasonic dissection, as described²⁰. Haemostasis and control of bile leaks was achieved by means of bipolar cautery coagulation, or ligation for small pedicles. Intermittent pedicle clamping was performed in the event of bleeding, or in some patients to obtain a bloodless operative field. Methylene blue injection through the cystic drain was performed selectively to rule out biliary leakage.

Postoperative data

After surgery, all patients were seen daily by a physician until hospital discharge. Liver function tests were performed on postoperative day (POD) 1, 3, 5, 7 and 10. Chest radiography was carried out routinely on POD 1 and 3 in all centres. Thoracoabdominopelvic CT with intravenous contrast injection was performed selectively in patients with suspected abdominal or thoracic complications. Specific liver-related complications were categorized as follows: liver failure was defined according to the '50–50 criteria' on POD 5²¹; ascites was defined as abdominal drainage output of more than 10 ml per kg per day 787

after POD 3²²; haemorrhage was defined as a reduction in haemoglobin level of more than 3 g/dl after the end of surgery, compared with postoperative baseline level, and/or any postoperative transfusion of packed red blood cell units for a falling haemoglobin concentration, and/or the need for invasive reintervention²³; finally, biliary leakage was defined by a bilirubin concentration in the drainage fluid more than threefold that in serum²⁴. Liver parenchyma was assessed according to the presence of both fibrosis and steatosis. Fibrosis score ranged from 0 to 425 and was considered severe in patients with stage F3 and F4, whereas steatosis was considered significant when above 30 per cent. Postoperative complications were stratified according to the Dindo-Clavien classification²⁶, which defines major complications by a score of III or more. Complications and operative mortality were considered as those occurring within 90 days of surgery, or at any time during the postoperative hospital stay.

Study design

Risk factors for conversion and postoperative complications were analysed. The influence of conversion on the postoperative course of patients undergoing LMH was then assessed by comparing the postoperative course of patients who had conversion with that of patients who did not, before and after propensity score adjustment for the risk factors for conversion. Using this propensity score matching method, the two groups would be similar in terms of preoperative characteristics along with risk factors for postoperative complications, thus allowing the effect of conversion on the postoperative course of the patients to be analysed. Finally, to determine whether conversion led to a more impaired postoperative course than planned laparotomy, the postoperative outcomes of patients who had conversion were compared with those of matched controls undergoing major liver resection at centre 3 during the same period, before and after propensity score adjustment on factors known to influence the type of approach (laparoscopy or laparotomy).

Statistical analysis

Quantitative variables are expressed as mean or median (range) as appropriate. Qualitative variables are expressed as frequencies. Mann–Whitney U test was used for intergroup comparisons of quantitative variables as appropriate, whereas the χ^2 test or Fisher's exact test was used to compare categorical data. Probabilities of undergoing conversion and experiencing postoperative complications were estimated using a multivariable logistic regression model. All variables that differed significantly in




Fig. 1 Resections and conversions in patients undergoing major laparoscopic hepatectomy according to year, 2000–2013

univariable analysis (P < 0.100), when comparing the two groups, were included in the logistic model and backward selection was applied. For propensity score analysis, the logistic regression model was based on the assessment of goodness-of-fit statistics proposed by Lemeshow and Hosmer²⁷. In this setting, for comparison of postoperative complication rates between patients who did, or did not have a conversion, propensity score adjustment was performed on the factors that were significantly associated with conversion on multivariable analysis. Similarly, for comparison of postoperative complication rates between patients who had a conversion and those who had open surgery, propensity score adjustment was performed on the factors known to influence the choice of approach. The latter included baseline characteristics (sex, age, American Society of Anesthesiologists (ASA) fitness grade, body mass index (BMI)), co-morbidities (diabetes, chronic obstructive pulmonary disease (COPD), ischaemic heart disease), presence of severe underlying fibrosis, indication for hepatectomy (malignant/benign disease, living donation), tumour characteristics (number, size), type of resection (right, left, extended right, extended left) and extent of resection (biliary and vascular reconstruction, associated hepatic and extrahepatic resection). Using these propensity scores, patients who had a conversion were randomly matched to patients who did not, and to patients who had planned open surgery using 1:7 and 1:10 interval matching methods respectively. Thereafter, the groups were compared to examine the balance between variables and whether there were statistical differences in baseline variables between the groups. Finally, after assuring the comparability of the groups, comparison of postoperative complication rates between the groups was performed using χ^2 or Fisher's

 Table 1 Timing of conversion according to the reason for conversion and type of conversion

	Before pedicular dissection (n = 5)	Between pedicular dissection and hilar plate section (n = 7)	After hilar plate section $(n = 18)$
Reason for conversion			
Bleeding	0 (0)	1 (14)	13 (72)
Failure to progress	0 (0)	6 (86)	3 (17)
Adhesions	3 (60)	0 (0)	0 (0)
Operative incident	0 (0)	0 (0)	2 (11)
Need for further exploration	2 (40)	0 (0)	0 (0)
Type of conversion			
Subcostal incision	2 (40)	2 (29)	14 (78)
J-shaped incision	2 (40)	4 (57)	0 (0)
Midline incision	1 (20)	1 (14)	2 (11)
Hand-assisted	0 (0)	0 (0)	2 (11)

Values in parentheses are percentages.

exact test as appropriate. All statistical analyses were performed with SPSS[®] version 20.0 (IBM, Armonk, New York, USA).

Results

A total of 223 patients underwent LMH during the study period; there were 135 men (60.5 per cent) and 88 women (39.5 per cent). Median age was 63.5 (23.9–86.2) years, and 35 patients (15.7 per cent) were aged over 75 years. Median BMI was 24.9 (15.9–35.5) kg/m²; 54 patients (24.2 per cent) had a BMI above 28 kg/m². Indications for liver resection were malignant disease in 197 patients (88.3 per cent), including colorectal liver metastases in 112 (50.2 per cent, hepatocellular carcinoma in 44 (19.7 per cent),

cholangiocarcinoma in 27 (12.1 per cent) and other types of malignancy in 14 (6.3 per cent). Before liver resection, 87 patients (39.0 per cent) received chemotherapy, comprising more than six cycles in 63 patients (28.3 per cent). Preoperative portal vein embolization (PVE) and transarterial chemoembolization (TACE) were performed in 45 (20.2 per cent) and 13 (5.8 per cent) patients respectively. A total of 11 patients (4.9 per cent) underwent sequential TACE-PVE. Of the 26 patients (11.7 per cent) operated on for benign lesions, indications for liver resection were liver cell adenoma in six patients (2.7 per cent), symptomatic focal nodular hyperplasia and mucinous cystadenoma in five (2.2 per cent) each, living donation and intrahepatic stones in two patients (0.9 per cent) each, and other types of benign lesions in the remaining six patients $(2 \cdot 2 \text{ per cent}).$

Major right-sided resections were performed in 160 patients (71.7 per cent); 33 (14.8 per cent) had removal of more than four hepatic segments. Associated wedge resection or radiofrequency ablation in the contralateral lobe was performed in 24 (10.8 per cent) and seven (3.1 per cent) patients respectively. Biliary and portal reconstructions were performed in eight (3.6 per cent) and one (0.4 per cent) patients respectively. Extrahepatic procedures were performed in 16 patients (7.2 per cent), and included diaphragmatic resections in nine (4.0 per cent), colonic resection in three (1.3 per cent), and distal pancreatectomy, duodenal resection, right adrenal gland resection and right nephrectomy in one patient each (0.4 per cent). *Fig. S1* (supporting information) provides a flow chart for the study.

Conversion to open hepatectomy

Conversion to laparotomy was required in 30 patients (13.5 per cent); their characteristics are shown in *Table S1* (supporting information). *Fig. 1* represents the evolution in the number of patients who underwent conversion per year. The conversion rate was no different between centres 1 and 2 (12 versus 18.5 per cent; P = 0.201). When the experience of each centre was divided in two periods of equal numbers of procedures (early versus late), the conversion rate remained stable over time (17 versus 11 per cent, P = 0.183 for centre 1; 11 versus 20 per cent, P = 0.530 for centre 2).

Table 1 summarizes the timing of conversion according to the reason for and the type of conversion. Although the most frequent reason for conversion was bleeding that was difficult to control laparoscopically, no critical situation due to massive acute bleeding from a major vascular structure was encountered. Failure to progress laparoscopically was related to the inability to expose pedicular structures correctly in four patients, difficult exposure during 789

parenchymal transection in three patients, and inability to dissect the hepatocaval confluence because of a large lesion in two patients. Of the three patients with tight adhesions, two had previously undergone open abdominal surgery including partial gastrectomy and left colectomy, and one patient had primary intraperitoneal adhesions related to familial Mediterranean fever. Operative incidents accounted for a pleural breach and a biliary injury in one patient each, and the need for further exploration was required for unexpected tumour spread in two patients.

Table 2 details the results of univariable and multivariable analyses of risk factors for conversion. In multivariable analysis, age above 75 years, diabetes, BMI greater than 28 kg/m^2 , tumour diameter above 10 cm and associated biliary reconstruction were significantly associated with an increased risk of conversion. More patients with a BMI above 28 kg/m^2 (24·8 per cent *versus* 11·3 per cent in the early period; P = 0.039) and with lesions greater than 10 cm (15·5 *versus* 6·6 per cent respectively; P = 0.043) were operated on during the latest period in both centres.

Postoperative outcomes

In the whole cohort, six patients (2.7 per cent) died during the postoperative period, including one in the conversion group (P = 0.815). Death was related to biliary peritonitis in three patients, liver failure in two and postoperative haemorrhage in one. Overall 117 patients (52.5 per cent) had postoperative complications, which were major in 51 patients (22.9 per cent). Table S2 (supporting information) details the results of univariable and multivariable analyses of the risk factors for postoperative complications. In univariable analysis, BMI above 28 kg/m², resection for cholangiocarcinoma, severe underlying fibrosis, resection of more than four hepatic segments, right-sided liver resection, associated radiofrequency ablation, conversion to laparotomy and abdominal drainage were significantly associated with increased rates of postoperative complications. In multivariable analysis, the existence of severe underlying fibrosis (hazard ratio (HR) 3.42, 95 per cent c.i. 2.55 to 5.87; P = 0.018), right-sided resection (HR 1.93, 1.00 to 3.73; P = 0.049), associated radiofrequency ablation (HR 4.38, 2.34 to 7.54; P = 0.004) and conversion to laparotomy (HR 2.83, 1.09 to 7.30; P = 0.026) remained significantly associated with an increased risk of postoperative complications.

Influence of conversion on postoperative course

Of the 30 patients who had conversion to open surgery, one (3 per cent) died after surgery and 23 (77 per cent) experienced postoperative complications,

Prespective characteristics View Age (versit)* 619 (239-66.2) 672 (419-65.2) 0.021 7.72 (167, 35.70) 0.009 Sex rate (M.F.) 118:75 17:13 0.6663 0.021 7.72 (167, 35.70) 0.009 Sax rate (M.F.) 118:75 17:13 0.6663 0.023 4.51 (116, 17.57) 0.030 Phypertension 51 (26-4) 12 (40) 0.124 0.012 0.010 Diabletes 20 (10-4) 9 (30) 0.021 4.51 (116, 17.57) 0.030 Matabolic syndrome 11 (5.7) 41 (13) 0.120 0.010 Matabolic syndrome 0.010 Cardiorespitatory oc-morbidity 38 (19.7) 5 (17) 0.113 0.0220 0.017 Corborati surgery 17 (62.2) 4 (13) 0.2220 0.010 0.0221 0.010 Corborati surgery 17 (16.1) 2 (7) 0.118 0.010 0.0220 0.010 0.0220 0.010 0.021 0.010 0.0220 0.010 0.010 0.021 0.010		No conversion ($n = 193$)	Conversion ($n = 30$)	P‡	Hazard ratio†	P#
Age (ward)* B19 (23.9-B62, 2) 672 (41.9-B5.2) 0.0359 (1.7, 72, (1.67, 35.70) 0.009 > 75 years 36 (15.5) 17, 13 0.600 0.021 7.72, (1.67, 35.70) 0.039 ASA fitness grade ≤ II 151 (78.2) 2.0 (87) 0.289 0.033 4.51 (1.16, 17.57) 0.030 Hypertamision 51 (24.4) 12 (40) 0.124 0.032 4.51 (1.16, 17.57) 0.030 Hypertamision 51 (24.4) 12 (40) 0.124 0.032 4.51 (1.16, 17.57) 0.030 Matizobic syndrome 11 (5.7) 4 (13) 0.120 0.220 0.201 0.202 0.201	Preoperative characteristics					
> 75 years 26 (13-6) 9 (30-0) 0.021 7.72 (1.67, 35-70) 0.009 Sex ratio (M:F) 115 (78-2) 26 (87) 0.289 Diabetes 20 (10-4) 9 (30) 0.003 4.51 (1-16, 17.57) 0.030 Hypertension 51 (22-4) 12 (40) 0.124 Diabetes 20 (10-4) 9 (30) 0.023 4.51 (1-16, 17.57) 0.030 Mit 28 (g/m² 40 (20 7) 14 (47) 0.022 6.41 (1.56, 26.37) 0.010 Cardiorespiratory co-motricitory		61.9 (23.9-86.2)	67.2 (41.9-85.2)	0·035¶	-	-
Sex ratio (M:F) 118:75 17:13 0.6003 ASA fitness grade ± II 151 (78.2) 26 (87) 0.289 Diabetes 20 (10.4) 9 (30) 0.033 4.51 (1-6, 17.57) 0.030 Hypertonsion 51 (26.4) 12 (40) 0.124 0.002 6.41 (1.56, 26.37) 0.010 Mattabolic syndrome 11 (57) 4 (13) 0.120 0.010 Mattabolic syndrome 11 (57) 4 (13) 0.120 Coronary heart disease 20 (10.4) 1 (3) 0.220 0.010 0.036 Coronary heart disease 20 (10.4) 1 (3) 0.220 0.011 0.010 0.010 Colorescial surgery 77 (18.9) 8 (27) 0.0165 0.017 0.017 Other 12 (62) 4 (13) 0.388 0.0165 0.013 0.754 Steatosis > 30(5.5) 4 (13) 0.764 0.023 0.023 0.023 Viral infector 16 (8.3) 11 (87) 0.121 0.023 0.023 Other 11 (57)			9 (30.0)		7.72 (1.67, 35.70)	0.009
AAA firmese grade ≤ 11 15 1 (78.2) 26 (87) 0.289 Diabetes 20 (10.4) 12 (40) 0.030 Hypertension 51 (26.4) 12 (40) 0.124 Displicationia 36 (18.7) 3 (10) 0.246 Stall S 28 (gint ²) 40 (20.7) 14 (47) 0.020 6.41 (1.56, 26.37) 0.010 Matabolic syndrome 11 (5.7) 4 (13) 0.120 6.41 (1.56, 26.37) 0.010 Cardionespictory co-morbiding surgery 15 (7.4) 5 (17) 0.666 5 0.010 Tobacco use 52 (26.9) 11 (67) 0.717 0.696 5 0.670 5 5 100 107 5 100 107 5 107 0.163 101 100 <td>-</td> <td></td> <td>· · /</td> <td></td> <td></td> <td></td>	-		· · /			
Diabeta 20 (10-4) 9 (20) 0.003 4-51 (1-16, 17-57) 0.030 Hypertension 51 (28.4) 12 (40) 0.124 0.012 Dyslipidearnia 36 (18.7) 12 (40) 0.020 0.010 Matabolic syndrom 11 (5.7) 4 (13) 0.0120 0.010 Cardionespiratory co-morbidity 38 (19.7) 5 (17) 0.060 0.0120 Coronary Meart disease 20 (10.4) 1 (8) 0.220 0.010 Coronary Meart disease 52 (26.9) 11 (37) 0.271 Previous abdominal surgery 170 (92.2) 14 (47) 0.107 Colorectal surgery 77 (39.9) 8 (27) 0.163 Underlying liver disease Underlying liver disease 10 (0) 0.428 Alorhol-related 37 (19.2) 6 (20) 0.915 10 (10.0) 10 (10.0) Viral infection 16 (8.3) 4 (13) 0.368 10 (10.0) 10 (10.0) 10 (10.0) 10 (10.0) 10 (10.0) 10 (10.0) 10 (10.0) 10 (10.0) 10 (10.0) 10 (10.0) 10 (10.0)				-		
Hypetransion 51 (26.4) 12 (40) 0.124 Dyslipidamia 66 (18.7) 14 (47) 0.002 6.41 (1.56, 26.37) 0.010 Mattabolic syndrome 11 (5.7) 4 (13) 0.120 6.41 (1.56, 26.37) 0.010 Cardionespitatory co-morbiding suggery 15 (7.8) 5 (17) 0.113 0.220 COPO 15 (7.8) 5 (17) 0.113 Tobacco use 52 (26.9) 11 (87) 0.271 0.162 14 (17) 0.178 Previous abdominal surgery 17 (08.2) 14 (13) 0.2428 14 (13) 0.2428 Underlying liver disease 37 (19.2) 6 (20) 0.915 14 (13) 0.2428 Underlying liver disease 37 (19.2) 6 (20) 0.915 14 (13) 0.338 Iron overload 4 (2.1) 0 (0) 0.426 38 (16) 16 (15) 16 (15) 16 (15) 16 (15) 16 (15) 16 (15) 16 (15) 16 (15) 16 (15) 16 (15) 16 (15) 16 (15) 16 (15) 17 (15) 16 (15) 16 (15) <td>-</td> <td></td> <td></td> <td></td> <td>4.51 (1.16, 17.57)</td> <td>0.030</td>	-				4.51 (1.16, 17.57)	0.030
Dspinplasmia 36 (16.7) 3 (10) 0.246 BMI > 28 kg/m² 40 (20.7) 14 (47) 0.002 6.41 (1.56, 26.37) 0.101 Matabolic syndrome 11 (6.7) 4 (13) 0.120 6.41 (1.56, 26.37) 0.101 Cardiorespiratory co-morbidity 38 (19.7) 5 (17) 0.66 6.41 (1.56, 26.37) 0.101 Coronary Heart disease 52 (26.9) 11 (37) 0.221 7 7 Previous abdominal surgery 120 (62.2) 14 (47) 0.107 6.000 1.4 1.4 1.4 1.4 1.4 1.4 1.6 1.4 1.6 1.4 1.6 </td <td></td> <td></td> <td></td> <td></td> <td>,</td> <td></td>					,	
BMI-28 kg/m² 40 (20.7) 14 (47) 0.02 6.41 (1.56, 26.37) 0.010 Metabolic syndrome 11 (6.7) 4 (13) 0.120 Cardiorespiratory co-morbidity 38 (19.7) 5 (17) 0.696 Coronary heart disease 20 (10.4) 1 (8) 0.220 COPD 51 (7.8) 0.277 0.113 Tobacco use 52 (26.9) 11 (37) 0.217 Cohercial surgery 77 (39.9) 8 (27) 0.165 Hepatic surgery 31 (16.1) 2 (7) 0.778 <t< td=""><td></td><td>· · · · ·</td><td></td><td></td><td></td><td></td></t<>		· · · · ·				
Metabolic syndrome 11 (6-7) 4 (13) 0.120 Cardiorespiratory co-morbidity 38 (19-7) 5 (17) 0.696 Coronary heart disease 20 (10-4) 1 (8) 0.220 COPD 15 (7.8) 5 (17) 0.113 Tobacco use 55 (26.9) 11 (8.7) 0.221 Previous abdominal surgery 120 (62.2) 14 (47) 0.107 Colorectal surgery 77 (39.9) 8 (27) 0.165 Hepatic surgery 31 (16-1) 2 (7) 0.178 Other 12 (6-2) 4 (13) 0.342 Underlying liver disease 1 4 (2.1) 0 (0) 0.426 Severe fibrosis 30 (15-5) 4 (13) 0.761 1 HCC 37 (19.2) 7 (23) 0.620 0.223 Coholarylicacarionna 12 (10.9) 6 (20) 0.761 1 HCC 37 (19.2) 7 (23) 0.623 1 1 Cohorbal 11 (6-7) 3 (10) 0.366 1 1 1 <td></td> <td></td> <td></td> <td></td> <td>6.41 (1.56, 26.37)</td> <td>0.010</td>					6.41 (1.56, 26.37)	0.010
Gardiorespiratory co-mobidity 38 (19-7) 5 (17) 0.066 Coronary heart disease 20 (10-4) 1 (3) 0.220 COPD 15 (7.8) 5 (17) 0.113 Tobacco use 52 (26-9) 11 (37) 0.271 Previous abdominal surgery 77 (39-9) 8 (27) 0.165 Hepatic surgery 31 (16-1) 2 (7) 0.178 Other 12 (62.2) 4 (13) 0.2425 Underlying liver disease	e e e e e e e e e e e e e e e e e e e				0 (1 00, 20 0.)	0010
Coronary heart disease 20 (10-4) 1 (8) 0.220 COPD 15 (7.8) 5 (17) 0.113 Tobacco use 52 (26.9) 11 (37) 0.271 Previous abdominal surgery 120 (82.2) 14 (47) 0.107 Colorectal surgery 77 (39.9) 8 (27) 0.165 Hepatic surgery 31 (16-1) 2 (7) 0.178 Other 12 (82) 4 (13) 0.368 Underlying liver disease 2 100 0.428 Alcohol-related 37 (19-2) 6 (20) 0.915 Viral infection 16 (8.3) 4 (13) 0.754 Steatoris> 50% 33 (17-1) 6 (20) 0.697 Pathody 7 7 (19.9) 6 (20) 0.238 Coloradi liver metastases 101 (62.3) 11 (37) 0.754 Steatoris> 50% 33 (17-1) 6 (20) 0.238 Coloradular hyperplasia 5 (2.6) 0 (0) 0.373 Other 11 (57) 3 (10) 0.761 Liv	-					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
Tobacco use 52 (28.9) 11 (37) 0.271 Previous abdominal surgery 120 (62.2) 14 (47) 0.107 Colorectal surgery 31 (16.1) 2 (7) 0.178 Hepatic surgery 31 (16.1) 2 (7) 0.178 Other 12 (62) 4 (13) 0.242 Underlying liver disease Alcohol-related 37 (19.2) 6 (20) 0.915 Viral infection 16 (8.3) 4 (13) 0.388 Iron overload 4 (2.1) 0 (0) 0.426 Severe fibrosis 30 (17.1) 6 (20) 0.697 Pathology Malignant disease 170 (88-1) 27 (90) 0.761 HCC 37 (19.2) 7 (23) 0.6235 Colorectal liver metasases 101 (52.3) 11 (37) 0.121 Other 11 (67) 3 (10) 0.761 Liver cell adenoma 6 (3.1) 0 (0) 0.373 Mucinous cystadenoma 4						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
Colorectal surgery 77 (39.9) 8 (27) 0.165 Hepatic surgery 31 (161) 2 (7) 0.178 Other 12 (62) 4 (13) 0.242§ Underlying liver disease Alcohol-related 37 (19.2) 6 (20) 0.915 Viral infection 16 (8.3) 4 (13) 0.368 Iron overload 4 (2.1) 0 (0) 0.426 Severe fibrosis 30 (15.5) 4 (13) 0.754 Steatosis > 30% 33 (17.1) 6 (20) 0.623 Pathology 7 (23) 0.623 Colorectal liver metastases 101 (52.3) 11 (37) 0.121 § Other 11 (57) 3 (10) 0.368 Benign disease 23 (1.19) 3 (10) 0.373 Uvier diedenoma 6 (3.1) 2 (7) 0.374 § Uvier diedenoma 6 (3.1) 2 (7) </td <td></td> <td>· · · · ·</td> <td></td> <td></td> <td></td> <td></td>		· · · · ·				
Hepatic surgery 31 (16.1) 2 (7) 0.178 Other 12 (6.2) 4 (13) 0.2425 Underlying liver disease						
Other 12 (6.2) 4 (13) 0.242§ Underlying liver disease						
$\begin{tabular}{ c c c c c c } \hline Underlying liver disease & U & U & U & U & U & U & U & U & U & $						
Alcohol-related 37 (19.2) 6 (20) 0.915 Viral infection 16 (8-3) 4 (13) 0.368 Icon overload 4 (2.1) 0 (0) 0.426 Severe fibrosis 30 (15.5) 4 (13) 0.754 Statosis > 30% 33 (17.1) 6 (20) 0.697 Pathology Malignant disease 170 (88.1) 27 (90) 0.761 HCC 37 (19.2) 7 (23) 0.623§ Cholanglocarcinoma 21 (10.9) 6 (20) 0.223§ Other 11 (5.7) 3 (10) 0.366 Benign disease 23 (1.1) 0 (0) 0.328 Focal nodular hyperplasia 5 (2.6) 0 (0) 0.373 Mucinous cystadenoma 4 (2.1) 1 (3) 0.518 Using donor 2 (1-0) 0 (0) 0.575§ 0.014		12 (0.2)	4 (13)	0.2428		
Viral infection 16 (8.3) 4 (13) 0.368 Iron overload 4 (2.1) 0 (0) 0.426 Severe fibrosis 30 (15-5) 4 (13) 0.754 Steatosis - 30% 33 (17-1) 6 (20) 0.697 Pathology Malignant disease 170 (88-1) 27 (90) 0.761 HCC 37 (19-2) 7 (23) 0.6235 Cholangiocarcinoma 21 (10-9) 6 (20) 0.2238 Colorectal liver metastases 101 (52.3) 11 (37) 0.1218 Other 11 (5.7) 3 (10) 0.761 Liver cell adenoma 6 (3.1) 0 (0) 0.333 Mucinous cystadenoma 4 (2.1) 1 (3) 0.518 Living donor 2 (1-0) 0 (0) 0.5758 Single lesion 99 (51-3) 19 (63) 0.219 Tumour diameter > 10cm 19 (9.8) 8 (27) 0.009 8-91 (1-57, 50.79) 0.014 Preoperative management Chemotherapy 80 (41-5)		27 (10.0)	C (00)	0.015		
Iron overload 4 (2,1) 0 (0) 0.426 Severe fibrosis 30 (15-5) 4 (13) 0.754 Steatosis > 30% 33 (17.1) 6 (20) 0.697 Pattology						
Severe fibrosis 30 (15) 4 (13) 0.754 Statosis > 30% 33 (17.1) 6 (20) 0.697 Pathology						
Steatosis > 30% 33 (17.1) 6 (20) 0.697 Pathology						
Pathology Malignant disease 170 (88.1) 27 (90) 0-761 HCC 37 (19-2) 7 (23) 0-623§ Cholangiocarcinoma 21 (10-9) 6 (20) 0-223§ Colorectal liver metastases 101 (52-3) 11 (37) 0-121§ Other 11 (6.7) 3 (10) 0-366 Benign disease 23 (11-9) 3 (10) 0-761 Liver cell adenoma 6 (3-1) 0 (0) 0-328 Focal nodular hyperplasia 5 (2-6) 0 (0) 0-575§ Other 6 (3-1) 2 (7) 0-374 Living donor 2 (1-0) 0 (0) 0.575§ Other 6 (3-1) 2 (7) 0.374§ Single lesion 99 (51-3) 19 (63) 0.219 Tumour diameter > 10 cm 19 (9-8) 8 (27) 0.009 8-91 (1-57, 50-79) 0-014 Preoperative management - - - - - - - - - 0.74 (0-18, 5-67) 0.321 > 6 (20) 0						
Mailgnant disease170 (88-1)27 (90)0.761HCC37 (19-2)7 (23)0.6238Cholangiocarcinoma21 (10-9)6 (20)0.2238Colorectal liver metastases101 (52-3)11 (37)0.1218Other11 (57)3 (10)0.366Benign disease23 (11-9)3 (10)0.761Liver cell adenoma6 (3-1)0 (0)0.328Focal nodular hyperplasia5 (2-6)0 (0)0.373Mucinous cystadenoma4 (2-1)1 (3)0.518Living donor2 (1-0)0 (0)0.5758Other6 (3-1)2 (7)0.3748Single lesion99 (51.3)19 (63)0.219Tumour diameter > 10 cm19 (9-8)8 (27)0.0098-91 (1-57, 50-79)0-014Preoperative management7 (23)0-07180-74 (0-18, 5-67)0-321> 6 cycles57 (29-5)6 (20)0.2815720 (7)0-6898PVE39 (20-2)6 (20)0.9791130.948Associated RFA6 (3-1)1 (3)0.9484444444444444444444445556666666566656666666666666666 <t< td=""><td></td><td>33 (17-1)</td><td>6 (20)</td><td>0.697</td><td></td><td></td></t<>		33 (17-1)	6 (20)	0.697		
HCC 37 (19-2) 7 (23) 0.623§ Cholangiocarcinoma 21 (10-9) 6 (20) 0.223§ Colorectal liver metastases 101 (52-3) 11 (37) 0.121§ Other 11 (5-7) 3 (10) 0.366 Benign disease 23 (11-9) 3 (10) 0.761 Liver cell adenoma 6 (3-1) 0 (0) 0.328 Focal nodular hyperplasia 5 (2-6) 0 (0) 0.373 Mucinous cystadenoma 4 (2-1) 1 (3) 0.518 Living donor 2 (1-0) 0 (0) 0.575§ Other 6 (3-1) 2 (7) 0.374§ Single lesion 99 (51-3) 19 (63) 0.219 Tumour diameter > 10 cm 19 (63) 0.219 0.74 (0.18, 5-67) 0.321 Preoperative management	0,		07 (00)	0 704		
$\begin{tabular}{ c c c c c c } \hline Cholangiocarcinoma & 21 (10.9) & 6 (20) & 0.223 \\ \hline Colorectal liver metastases & 101 (52.3) & 11 (37) & 0.121 \\ \hline Other & 11 (5.7) & 3 (10) & 0.366 \\ \hline Benign disease & 23 (11.9) & 3 (10) & 0.761 \\ \hline Liver cell adenoma & 6 (3.1) & 0 (0) & 0.328 \\ \hline Focal nodular hyperplasia & 5 (2.6) & 0 (0) & 0.373 \\ \hline Mucinous cystadenoma & 4 (2.1) & 1 (3) & 0.518 \\ \hline Living donor & 2 (1.0) & 0 (0) & 0.575 \\ \hline Other & 6 (3.1) & 2 (7) & 0.374 \\ \hline Single lesion & 99 (51.3) & 19 (63) & 0.219 \\ \hline Tumour diameter > 10 cm & 19 (9.8) & 8 (27) & 0.009 & 8.91 (1.57, 50.79) & 0.014 \\ \hline Preoperative management & & & & & & & & & & & & & & & & & & &$	-					
Colorectal liver metastases 101 (52·3) 11 (37) 0.121 § Other 11 (5-7) 3 (10) 0-366 Benign disease 23 (11·9) 3 (10) 0-761 Liver cell adenoma 6 (3·1) 0 (0) 0-328 Focal nodular hyperplasia 5 (2·6) 0 (0) 0-373 Mucinous cystadenoma 4 (2·1) 1 (3) 0-518 Living donor 2 (1·0) 0 (0) 0.575 § Other 6 (3·1) 2 (7) 0.374 § Single lesion 99 (51.3) 19 (63) 0.21 9 Tumour diameter > 10 cm 19 (9·8) 8 (27) 0.009 8·91 (1·57, 50·79) 0.014 Preoperative management U U 0.009 8·91 (1·57, 50·79) 0.014 TACE 11 (5·7) 2 (7) 0.688 § 0.99 9 PVE 39 (20·2) 6 (20) 0.97 § 0.74 (0·18, 5·67) 0.321 > 6 cycles 57 (29·5) 6 (20) 0.97 § 0.74 (0·18, 5·67) 0.321 TACE				-		
Other 11 (5-7) 3 (10) 0.366 Benign disease 23 (11-9) 3 (10) 0.761 Liver cell adenoma 6 (3-1) 0 (0) 0.328 Focal nodular hyperplasia 5 (2-6) 0 (0) 0.373 Mucinous cystadenoma 4 (2-1) 1 (3) 0.518 Living donor 2 (1-0) 0 (0) 0.575§ Other 6 (3.1) 2 (7) 0.374§ Single lesion 99 (51-3) 19 (63) 0.219 Tumour diameter > 10 cm 19 (9-8) 8 (27) 0.009 8-91 (1-57, 50-79) 0.014 Preoperative management	· ·			-		
Benign disease 23 (11-9) 3 (10) 0.761 Liver cell adenoma 6 (3·1) 0 (0) 0.328 Focal nodular hyperplasia 5 (2·6) 0 (0) 0.373 Mucinous cystadenoma 4 (2·1) 1 (3) 0.518 Living donor 2 (1·0) 0 (0) 0.575§ Other 6 (3·1) 2 (7) 0.374§ Single lesion 99 (51·3) 19 (63) 0.219 Tumour diameter > 10 cm 19 (9·8) 8 (27) 0.009 8·91 (1·57, 50·79) 0·014 Preoperative management				-		
Liver cell adenoma 6 (3.1) 0 (0) 0.328 Focal nodular hyperplasia 5 (2.6) 0 (0) 0.373 Mucinous cystadenoma 4 (2.1) 1 (3) 0.518 Living donor 2 (1.0) 0 (0) 0.575§ Other 6 (3.1) 2 (7) 0.374§ Single lesion 99 (51.3) 19 (63) 0.219 Tumour diameter > 10 cm 19 (8) 8 (27) 0.00 8.91 (1.57, 50.79) 0.014 Preoperative management U U 0.723 0.071§ 0.74 (0.18, 5.67) 0.321 > 6 cycles 57 (29.5) 6 (20) 0.281 0.321 0.74 (0.18, 5.67) 0.321 > 6 cycles 57 (29.5) 6 (20) 0.281 0.74 (0.18, 5.67) 0.321 TACE 11 (5.7) 2 (7) 0.689§ 0.99 1.01 0.91 Intraoperative characteristics VE 39 (20.2) 6 (20) 0.979 1.01 1.3 0.4948 Associated RFA 6 (3.1) 1 (3) 0.4948 Associated						
Focal nodular hyperplasia 5 (2-6) 0 (0) 0.373 Mucinous cystadenoma 4 (2·1) 1 (3) 0.518 Living donor 2 (1·0) 0 (0) 0.575 § Other 6 (3·1) 2 (7) 0.374 § Single lesion 99 (51·3) 19 (63) 0.219 Tumour diameter > 10 cm 19 (9·8) 8 (27) 0.009 8·91 (1·57, 50·79) 0·014 Preoperative management 0.071 § 0.74 (0·18, 5·67) 0·321 > 6 cycles 57 (29·5) 6 (20) 0·281 TACE 11 (5·7) 2 (7) 0.689 § </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Mucinous cystatement 4 (2·1) 1 (3) 0-518 Living donor 2 (1·0) 0 (0) 0-575§ Other 6 (3·1) 2 (7) 0.374§ Single lesion 99 (51·3) 19 (63) 0-219 Tumour diameter > 10 cm 19 (9·8) 8 (27) 0.009 8·91 (1·57, 50·79) 0.014 Preoperative management 7 (23) 0.071§ 0.74 (0·18, 5·67) 0.321 > 6 cycles 57 (29·5) 6 (20) 0.281						
Living donor2 (1.0)0 (0)0.575 §Other6 (3.1)2 (7)0.374 §Single lesion99 (51.3)19 (63)0.219Tumour diameter > 10 cm19 (9.8)8 (27)0.0098.91 (1.57, 50.79)0.014Preoperative management $-7 (23)$ 0.071 §0.74 (0.18, 5.67)0.321> 6 cycles57 (29.5)6 (20)0.281 $-74 (0.18, 5.67)$ 0.321> 6 cycles57 (29.5)6 (20)0.979 $-74 (0.18, 5.67)$ 0.321PVE39 (20.2)6 (20)0.979 $-74 (0.18, 5.67)$ 0.321> 4 resected segments26 (13.5)7 (23)0.169 § $-74 (0.18, 5.67)$ $-74 (0.18, 5.67)$ $-74 (0.18, 5.67)$ National construction140 (72.5)2 (7)0.689 § $-74 (0.18, 5.67)$ $-74 (0.18, 5.67)$ $-74 (0.18, 5.67)$ $-74 (0.18, 5.67)$ $-74 (0.18, 5.67)$ PVE39 (20.2)6 (20)0.979 $-74 (0.18, 5.67)$						
$\begin{array}{c c c c c c c } \hline Other & 6 (3 \cdot 1) & 2 (7) & 0 \cdot 374 \\ \hline Single lesion & 99 (51 \cdot 3) & 19 (63) & 0 \cdot 219 \\ \hline Tumour diameter > 10 cm & 19 (9 \cdot 8) & 8 (27) & 0 \cdot 009 & 8 \cdot 91 (1 \cdot 57, 50 \cdot 79) & 0 \cdot 014 \\ \hline Preoperative management & & & & & & & & & & & & & & & & & & &$						
Single lesion 99 (51.3) 19 (63) 0.219 Tumour diameter > 10 cm 19 (9.8) 8 (27) 0.009 8.91 (1.57, 50.79) 0.014 Preoperative management 0.071 § 0.74 (0.18, 5.67) 0.321 > 6 cycles 57 (29.5) 6 (20) 0.281 TACE 11 (5.7) 2 (7) 0.689§ <	-			-		
Tumour diameter > 10 cm 19 (9-8) 8 (27) 0.009 8.91 (1.57, 50.79) 0.014 Preoperative management				-		
Preoperative management 80 (41.5) 7 (23) 0.071 § 0.74 (0.18, 5.67) 0.321 > 6 cycles 57 (29.5) 6 (20) 0.281 TACE 11 (5.7) 2 (7) 0.689 § PVE 39 (20.2) 6 (20) 0.979 Intraoperative characteristics 26 (13.5) 7 (23) 0.169 § Right-sided hepatectomy 140 (72.5) 20 (67) 0.506 Associated RFA 6 (3.1) 1 (3) 0.948 Associated wedge resection 21 (10.9) 3 (10) 0.885 Biliary reconstruction 4 (2.1) 4 (13) 0.013 § 13.99 (1.82, 238.13) 0.048 Vascular reconstruction 0 (0) 1 (3) 0.135 § 0.135 § 0.135 §	· ·					
Chemotherapy 80 (41-5) 7 (23) 0-071§ 0-74 (0-18, 5-67) 0-321 > 6 cycles 57 (29-5) 6 (20) 0-281 1	Tumour diameter > 10 cm	19 (9-8)	8 (27)	0.009	8.91 (1.57, 50.79)	0.014
> 6 cycles 57 (29.5) 6 (20) 0.281 TACE 11 (5.7) 2 (7) 0.689§ PVE 39 (20.2) 6 (20) 0.979 Intraoperative characteristics 54 resected segments 26 (13.5) 7 (23) 0.169§ Right-sided hepatectomy 140 (72.5) 20 (67) 0.506 4ssociated RFA 6 (3.1) 1 (3) 0.948 Associated wedge resection 21 (10.9) 3 (10) 0.885 13.99 (1.82, 238.13) 0.048 Biliary reconstruction 4 (2.1) 4 (13) 0.013§ 13.99 (1.82, 238.13) 0.048						
TACE 11 (5-7) 2 (7) 0-689§ PVE 39 (20-2) 6 (20) 0.979 Intraoperative characteristics - - > 4 resected segments 26 (13-5) 7 (23) 0-169§ Right-sided hepatectomy 140 (72-5) 20 (67) 0-506 Associated RFA 6 (3-1) 1 (3) 0-948 Associated wedge resection 21 (10-9) 3 (10) 0-885 Biliary reconstruction 4 (2-1) 4 (13) 0-013§ 13-99 (1-82, 238-13) 0-048 Vascular reconstruction 0 (0) 1 (3) 0-135§ 0-048	Chemotherapy	80 (41.5)	7 (23)	-	0.74 (0.18, 5.67)	0.321
PVE 39 (20·2) 6 (20) 0.979 Intraoperative characteristics - <td< td=""><td>-</td><td>57 (29.5)</td><td></td><td></td><td></td><td></td></td<>	-	57 (29.5)				
Intraoperative characteristics 26 (13.5) 7 (23) 0.169§ > 4 resected segments 26 (13.5) 7 (23) 0.169§ Right-sided hepatectomy 140 (72.5) 20 (67) 0.506 Associated RFA 6 (3.1) 1 (3) 0.948 Associated wedge resection 21 (10.9) 3 (10) 0.885 Biliary reconstruction 4 (2.1) 4 (13) 0.013§ 13.99 (1.82, 238.13) 0.048 Vascular reconstruction 0 (0) 1 (3) 0.135§ 13.99 (1.82, 238.13) 0.048				0		
> 4 resected segments 26 (13.5) 7 (23) 0.169§ Right-sided hepatectomy 140 (72.5) 20 (67) 0.506 Associated RFA 6 (3.1) 1 (3) 0.948 Associated wedge resection 21 (10.9) 3 (10) 0.885 Biliary reconstruction 4 (2.1) 4 (13) 0.013§ 13.99 (1.82, 238.13) 0.048 Vascular reconstruction 0 (0) 1 (3) 0.135§ 0.0135§ 0.0135§	PVE	39 (20·2)	6 (20)	0.979		
Right-sided hepatectomy 140 (72-5) 20 (67) 0.506 Associated RFA 6 (3·1) 1 (3) 0.948 Associated wedge resection 21 (10·9) 3 (10) 0.885 Biliary reconstruction 4 (2·1) 4 (13) 0.013§ 13·99 (1·82, 238·13) 0.048 Vascular reconstruction 0 (0) 1 (3) 0.135§ 13.99 1.82, 238·13) 0.048	Intraoperative characteristics					
Associated RFA 6 (3 · 1) 1 (3) 0 · 948 Associated wedge resection 21 (10 · 9) 3 (10) 0 · 885 Biliary reconstruction 4 (2 · 1) 4 (13) 0 · 013§ 13 · 99 (1 · 82, 238 · 13) 0 · 048 Vascular reconstruction 0 (0) 1 (3) 0 · 135§ 13 · 99 (1 · 82, 238 · 13) 0 · 048	_			-		
Associated wedge resection 21 (10·9) 3 (10) 0.885 Biliary reconstruction 4 (2·1) 4 (13) 0.013§ 13·99 (1·82, 238·13) 0.048 Vascular reconstruction 0 (0) 1 (3) 0.135§ 13.99 (1.82, 238·13) 0.048		140 (72.5)	20 (67)			
Biliary reconstruction 4 (2·1) 4 (13) 0·013§ 13·99 (1·82, 238·13) 0·048 Vascular reconstruction 0 (0) 1 (3) 0·135§ 13·99 (1·82, 238·13) 13·99 (1·	Associated RFA	6 (3.1)	1 (3)	0.948		
Vascular reconstruction 0 (0) 1 (3) 0.135§	Associated wedge resection	21 (10.9)	3 (10)	0.885		
	Biliary reconstruction	4 (2.1)		0·013§	13.99 (1.82, 238.13)	0.048
Extrahepatic procedure 13 (6-7) 3 (10) 0-519	Vascular reconstruction	0 (0)	1 (3)	0·135§		
	Extrahepatic procedure	13 (6.7)	3 (10)	0.519		

 Table 2 Univariable and multivariable analyses of risk factors for conversion to laparotomy

Values in parentheses are percentages unless indicated otherwise; *values are mean (range) and †95 per cent c.i. in parentheses. ASA, American Society of Anesthesiologists; BMI, body mass index; COPD, chronic obstructive pulmonary disease; HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; PVE, portal vein embolization; RFA, radiofrequency ablation. $\pm\chi^2$ test, except §Fisher's exact test and ¶Mann–Whitney U test; #logistic regression analysis.

	· ·	c ·	<i>c</i> ·	1 .	1 • 1• •
Table 3	Comparison	of postoperative	e course of patier	its undergoing	laparoscopic liver resection
	Companioon	or postoperativ	e course or putter	no una orgonig	input obcopie inter resection

	No conversion group	Conversion group	P ‡
Overall cohort	<i>n</i> = 193	n = 30	
Postoperative complications	94 (48.7)	23 (77)	0.005§
Dindo-Clavien grade I-II	52 (26.9)	14 (47)	0.033§
Dindo-Clavien grade III-IV	37 (19-2)	8 (27)	0.341
Postoperative mortality	5 (2.6)	1 (3)	0.815
Ascites	12 (6·2)	4 (13)	0·242§
Liver failure	7 (3.6)	1 (3)	0.936
Abdominal collection	41 (21.2)	7 (23)	0⋅813§
Biliary leakage	26 (13.5)	6 (20)	0·256§
Infectious complication	41 (21.2)	8 (27)	0∙485§
Respiratory complication	30 (15.5)	9 (30)	0.069§
Confusion	5 (2.6)	4 (13)	0.021§
Renal failure	6 (3.1)	4 (13)	0.032§
Haemorrhage	2 (1.0)	0 (0)	0.575
Multiple organ failure	8 (4.1)	3 (10)	0·171§
Reoperation	8 (4.1)	1 (3)	0·834§
Duration of surgery (min)*	297 (100-540)	348 (180–480)	0.017¶
Blood loss (ml)*	302 (50-1600)	623 (50-4500)	< 0.001
Transfusion	20 (10.4)	9 (30)	0.003
Hospital stay (days)*	10 (3-82)	12 (5–49)	0·094¶
After propensity score adjustment†	n = 112	<i>n</i> = 16	
Postoperative complications	53 (47.3)	12 (75)	0.038
Dindo-Clavien grade I-II	32 (28.6)	6 (38)	0.465
Dindo-Clavien grade III-IV	18 (16-1)	6 (38)	0.040
Postoperative mortality	3 (2.7)	0 (0)	0.508
Ascites	6 (5.4)	3 (19)	0.050
Liver failure	4 (3.6)	0 (0)	0.442
Abdominal collection	24 (21.4)	4 (25)	0.746
Biliary leakage	15 (13.4)	4 (25)	0.222
Infectious complication	23 (20.5)	5 (31)	0.332
Respiratory complication	15 (13.4)	3 (19)	0.564
Confusion	3 (2.7)	2 (13)	0·121§
Renal failure	4 (3.6)	2 (13)	0.114
Haemorrhage	1 (0.9)	0 (0)	0·702§
Multiple organ failure	5 (4.5)	0 (0)	0·384§
Reoperation	6 (5.4)	1 (6)	0·897§
Duration of surgery (min)*	302 (100-520)	363 (180–480)	0.032¶
Blood loss (ml)*	387 (50–1600)	616 (50-4500)	< 0.001
Transfusion	13 (11.6)	5 (31)	0.038
Hospital stay (days)*	10 (3-82)	13 (5-49)	0.063¶

Values in parentheses are percentages unless indicated otherwise; *values are median (range). \dagger Propensity score adjustment was performed on the factors influencing the risk of conversion as defined by the results of multivariable analysis; these included body mass index above 28 kg/m², diabetes, age above 75 years and associated biliary reconstruction. $\ddagger\chi^2$ test, except §Fisher's exact test and ¶Mann–Whitney U test.

including nine major complications (30 per cent). Neither the timing of conversion (P=0.624 for comparison between the three time periods) nor the reason for conversion (P=0.749 for comparison between the five reasons) influenced the postoperative complication rate.

Comparison of outcomes in patients who had conversion and those who did not

Table 3 details the results of the comparison of the postoperative course between patients who had a conversion and those who did not, before and after propensity score adjustment on factors associated with conversion. After propensity score adjustment, patients who underwent conversion had significantly more blood loss and transfusions than patients who did not. Likewise, the rates of overall and major postoperative complications, and postoperative ascites, were increased in the conversion group. Finally, matched patients in the conversion and no-conversion groups operated on for malignant disease had similar rates of surgical margin clearance (86 *versus* 92.9 per cent

	Laparotomy group	Conversion group	P‡
Overall cohort	n=770	n=30	
Postoperative complications	532 (69.1)	23 (77)	0·427§
Dindo-Clavien grade I-II	323 (41.9)	14 (47)	0·707§
Dindo-Clavien grade III-IV	172 (22.3)	8 (27)	0.577
Postoperative mortality	37 (4.8)	1 (3)	0.710
Ascites	230 (29.9)	4 (13)	0·064§
Liver failure	23 (3.0)	1 (3)	0.606§
Abdominal collection	80 (10.4)	7 (23)	0.036§
Biliary leakage	73 (9.5)	6 (20)	0·108§
Infectious complication	205 (26.6)	8 (27)	0.996
Respiratory complication	320 (41.6)	9 (30)	0·258§
Confusion	71 (9·2)	4 (13)	0.516§
Renal insufficiency	71 (9.2)	4 (13)	0.516§
Haemorrhage	33 (4-3)	0 (0)	0.630§
Multiple organ failure	49 (6-4)	3 (10)	0·437§
Reoperation	48 (6·2)	1 (3)	0.516
Duration of surgery (min)*	360 (150–980)	348 (180–480)	0·591¶
Blood loss (ml)*	610 (50-7500)	623 (50-4500)	0·653¶
Transfusion	182 (23.7)	9 (30)	0.422
Hospital stay (days)*	13 (2–96)	12 (5–49)	0·871¶
After propensity score adjustment [†]	<i>n</i> = 190	<i>n</i> = 19	
Postoperative complications	129 (67.9)	15 (79)	0·438§
Dindo-Clavien grade I-II	103 (54·2)	11 (58)	0.758
Dindo-Clavien grade III-IV	21 (11.1)	4 (21)	0·204§
Postoperative mortality	5 (2.6)	0 (0)	0.474
Ascites	49 (25.8)	3 (16)	0.336
Liver failure	4 (2.1)	0 (0)	0.523
Abdominal collection	19 (10.0)	5 (26)	0.033
Biliary leakage	12 (6·3)	4 (21)	0.021
Infectious complication	55 (28.9)	7 (37)	0.473
Respiratory complication	68 (35.8)	6 (32)	0.714
Confusion	20 (10.5)	3 (16)	0.485
Renal insufficiency	14 (7.4)	3 (16)	0.200
Haemorrhage	7 (3.7)	0 (0)	0.393
Multiple organ failure	7 (3.7)	1 (5)	0·542§
Reoperation	9 (4.7)	1 (5)	0·922§
Duration of surgery (min)*	312 (150–660)	335 (180–480)	0·526¶
Blood loss (ml)*	586 (50-5200)	612 (50-4500)	0.627¶
Transfusion	42 (22.1)	5 (26)	0·684§
Hospital stay (days)*	13 (2–96)	13 (5–49)	0·772¶

 Table 4 Postoperative course of patients who underwent conversion and patients who had planned laparotomy

Values in parentheses are percentages unless indicated otherwise; *values are median (range). \dagger Propensity score adjustment was performed on variables that are likely to influence the choice of the approach, including: baseline characteristics (sex, age, American Society of Anesthesiologists fitness grade, body mass index), co-morbidities (diabetes, chronic obstructive pulmonary disease, ischaemic heart disease), presence of severe underlying fibrosis, indication for hepatectomy (malignant or benign disease, living donation), tumour characteristics (number, size), type of resection (right, left, extended right, extended left) and extent of resection (biliary and vascular reconstruction, associated hepatic and extrahepatic resection). $\ddagger\chi^2$ test, except §Fisher's exact test and ¶Mann–Whitney U test.

respectively; P = 0.327) and surgical margin width (mean 1.2 *versus* 1.0 cm; P = 0.470).

Comparison of outcomes in patients who had conversion and those who had planned laparotomy

Comparison of the preoperative and operative characteristics of patients who had conversion and those who underwent planned laparotomy is provided in *Table S3* (supporting information). Before propensity score adjustment, these two groups were not comparable in terms of baseline characteristics and indications for

surgery, as patients in the conversion group were significantly older (67·2 versus 55·4 years in the laparotomy group; P < 0.001), more frequently had an ASA grade above II (13 versus 4·4 per cent respectively; P = 0.024), BMI above 28 kg/m² (47 versus 17·3 per cent; P < 0.001), metabolic syndrome (13 versus 3·5 per cent; P < 0.001) or COPD (17 versus 2·6 per cent; P < 0.001), and were more frequently operated on for malignant disease (90 versus 69·4 per cent; P = 0.015). Conversely, there were no significant differences between these two groups regarding operative characteristics, apart from the rates of inflow clamping and abdominal drainage. After propensity score matching, the two groups were comparable in terms of baseline characteristics, indications for surgery and operative characteristics.

Table 4 summarizes the comparison of the postoperative course of patients who had conversion and patients who underwent planned laparotomy before and after propensity score adjustment. After propensity score adjustment, there was no significant difference in the rates of overall, major and pulmonary postoperative complications between the two groups. However, patients who underwent a conversion more frequently had abdominal collections and biliary leakage than those who had a planned laparotomy. Finally, matched patients in the conversion and planned laparotomy groups operated on for malignant disease had similar rates of surgical margin clearance (84 *versus* 80·9 per cent respectively; P = 0.693) and surgical margin width (mean 1.3 *versus* 1.1 cm; P = 0.559).

Discussion

In the present study, conversion during LMH occurred in 13.5 per cent of the patients. Patient age, existence of diabetes, raised BMI, large lesion size and associated biliary reconstruction were identified as risk factors for conversion. In this setting, conversion was associated with a worse postoperative outcome compared with fully laparoscopic liver resection, but provided almost the same outcomes as planned open major hepatectomy.

Intuitively, conversion would occur more frequently during the early experience of LMH. In the present study, however, the conversion rate was stable throughout the study period. The explanation for this may be twofold. First, at both centres, LMH was attempted only after a certain expertise in LLR had been acquired²⁸. This finding emphasizes the necessary learning curve for LMH, even for surgeons who are familiar with laparoscopic minor liver resection. Second, indications for laparoscopy increased dramatically over time, with more complex procedures, more patients with increased BMI, as well as patients with large lesions. In these patients, exposure can sometimes be difficult in the upper part of the transection plane or even during final liver mobilization, as attested by the high incidence of conversion during the latest steps of the procedure rather than during pedicular dissection. Thus, even though it is likely that increasing expertise will help overcome traditional contraindications to the laparoscopic approach, such as the need for biliary or vascular reconstruction, the present results suggest that surgeons will still be confronted with considerable difficulties during parenchymal transection.

793

In patients undergoing LMH, the question of whether conversion leads to more postoperative complications than when conversion is not needed has, to date, remained unanswered. In colorectal surgery, it has been reported²⁹ that, although patients who underwent conversion experienced greater blood loss, increased time to first bowel movement and longer length of stay than those who did not, this did not result in increased rates of transfusion or postoperative complications. In the present study, as in previous ones¹⁶, the main indication for conversion was haemorrhage. In this context, patients who had a conversion logically experienced more blood loss and had higher transfusion rates than matched patients who did not. Similarly, patients who underwent conversion had more postoperative complications, especially pulmonary complications, and a trend towards a longer hospital stay than patients who did not undergo conversion. This finding is probably related to the fact that the majority of the patients underwent conversion through subcostal or J-shaped incisions. These incisions require transection of abdominal muscles and prolonged retraction of the right hemidiaphragm, and result in painful limitation of inhalation. In addition, the majority of conversions occurred during parenchymal transection after considerable operating time. Hence, to improve the postoperative tolerance and limit the negative effects of both conversion and prolonged surgery³⁰, a hybrid approach with laparoscopic pedicular dissection and open parenchymal transection using a minilaparotomy through a midline incision facilitated by a hanging manoeuvre³¹⁻³³ could be attractive in the presence of risk factors for conversion. This seems particularly relevant for large lesions, where extraction of the resected specimen may be challenging.

Determining whether conversion is associated with impaired outcomes compared with planned laparotomy is of crucial importance as it could represent a strong argument against the laparoscopic approach in patients requiring major hepatectomy. In the present study, however, patients who underwent conversion experienced similar blood loss and transfusion rates as matched patients who had planned laparotomy. This result suggests that the combination of low central venous pressure and pneumoperitoneum limits the consequences of vascular injury^{11,34} to some extent, and allows conversion to be performed safely in difficult situations. In the same way, overall postoperative complications and hospital stay were identical between patients who had conversion and those who underwent laparotomy, similar to what is observed in colorectal surgery^{29,35}, and thus further confirms that a considerable amount of the morbidity related to conversion was the consequence of the incision itself. However, it should be noted that patients who had conversion experienced significantly higher rates of postoperative biliary leakage and abdominal collection than matched patients who had a laparotomy. Interestingly, this striking difference was not observed between patients who underwent conversion and those who did not. Therefore, whether this finding is related to the conversion itself, or rather represents an inherent limitation of the laparoscopic approach, will have to be assessed in further studies. Nevertheless, this observation highlights that specific emphasis should be given to control of bile leaks in patients having laparoscopic major resection, particularly in the event of conversion. Likewise, increased awareness with liberal use of abdominal CT is required during the postoperative period for early detection of deep infectious complications in these patients.

The present study has several limitations. First, its retrospective nature and the relatively small number of events, especially after propensity score matching, might have led to insufficient statistical power in the analysis of the consequences of conversion on the postoperative course of patients, with the possibility of a type II error. In addition, the limited number of patients experiencing conversion precluded the drawing of solid conclusions regarding the impact of both timing and type of conversion on the postoperative results. Second, data regarding initial LMH procedures were not available for one of the centres. This may have led to underestimation of the overall rates of conversion. However, as the conversion rate appears to parallel the complexity of the cases, it is likely that conversion does not truly reflect the learning curve in laparoscopic major liver resection, which limits the consequences of this bias. Finally, patients undergoing open major hepatectomy in centres 1 and 2 were not analysed. As no patient had major LLR at centre 3 during the study period, potential corresponding controls were more likely to be found in this centre than in centres 1 and 2, where open resection was performed only when laparoscopy was contraindicated.

Acknowledgements

F.C. and D.F. contributed equally to this publication. *Disclosure:* The authors declare no conflict of interest.

References

- Buell JF, Cherqui D, Geller DA, O'Rourke N, Iannitti D, Dagher I *et al.*; World Consensus Conference on Laparoscopic Surgery. The international position on laparoscopic liver surgery: The Louisville Statement, 2008. *Ann Surg* 2009; **250**: 825–830.
- 2 Cheung TT, Poon RT, Yuen WK, Chok KS, Jenkins CR, Chan SC *et al*. Long-term survival analysis of pure

laparoscopic *versus* open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience. *Ann Surg* 2013; **257**: 506–511.

- 3 Topal B, Fieuws S, Aerts R, Vandeweyer H, Penninckx F. Laparoscopic *versus* open liver resection of hepatic neoplasms: comparative analysis of short-term results. *Surg Endosc* 2008; **22**: 2208–2213.
- 4 Belli G, Limongelli P, Fantini C, D'Agostino A, Cioffi L, Belli A *et al*. Laparoscopic and open treatment of hepatocellular carcinoma in patients with cirrhosis. *Br J Surg* 2009; **96**: 1041–1048.
- 5 Xiong JJ, Altaf K, Javed MA, Huang W, Mukherjee R, Mai G et al. Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma. *World J Gastroenterol* 2012; 18: 6657–6668.
- 6 Hirokawa F, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K *et al.* Short- and long-term outcomes of laparoscopic *versus* open hepatectomy for small malignant liver tumors: a single-center experience. *Surg Endosc* 2015; 29: 458–465.
- 7 Fuks D, Cauchy F, Ftériche S, Nomi T, Schwarz L, Dokmak S *et al*. Laparoscopy decreases pulmonary complications in patients undergoing major liver resection: a propensity score analysis. *Ann Surg* 2015; [Epub ahead of print].
- 8 Tranchart H, Di Giuro G, Lainas P, Roudie J, Agostini H, Franco D *et al*. Laparoscopic resection for hepatocellular carcinoma: a matched-pair comparative study. *Surg Endosc* 2010; 24: 1170–1176.
- 9 Truant S, Bouras AF, Hebbar M, Boleslawski E, Fromont G, Dharancy S *et al*. Laparoscopic resection *vs*. open liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: a case-matched study. *Surg Endosc* 2011; **25**: 3668–3677.
- 10 López-Ben S, Palacios O, Codina-Barreras A, Albiol MT, Falgueras L, Castro E *et al*. Pure laparoscopic liver resection reduces surgical site infections and hospital stay. Results of a case-matched control study in 50 patients. *Langenbecks Arch Surg* 2014; **399**: 307–314.
- 11 Dagher I, O'Rourke N, Geller DA, Cherqui D, Belli G, Gamblin TC *et al*. Laparoscopic major hepatectomy: an evolution in standard of care. *Ann Surg* 2009; **250**: 856–860.
- 12 Soubrane O, Schwarz L, Cauchy F, Perotto LO, Brustia R, Bernard D *et al*. A conceptual technique for laparoscopic right hepatectomy based on facts and oncological rules: the caudal approach. *Ann Surg* 2014; [Epub ahead of print].
- 13 Medbery RL, Chadid TS, Sweeney JF, Knechtle SJ, Kooby DA, Maithel SK *et al*. Laparoscopic *vs* open right hepatectomy: a value-based analysis. *J Am Coll Surg* 2014; 18: 929–939.
- 14 Tzanis D, Shivathirthan N, Laurent A, Abu Hilal M, Soubrane O, Kazaryan AM *et al*. European experience of laparoscopic major hepatectomy. *J Hepatobiliary Pancreat Sci* 2013; 20: 120–124.
- 15 Dagher I, Gayet B, Tzanis D, Tranchart H, Fuks D, Soubrane O *et al*. International experience for laparoscopic

major liver resection. *J Hepatobiliary Pancreat Sci* 2014; **21**: 732–736.

- Nguyen KT, Gamblin TC, Geller DA. World review of laparoscopic liver resection – 2804 patients. *Ann Surg* 2009; 250: 831–841.
- 17 Couinaud C. Le Foie: Etudes Anatomiques et Chirurgicales. Masson: Paris, 1957.
- 18 Jones RM, Moulton CE, Hardy KJ. Central venous pressure and its effect on blood loss during liver resection. *Br J Surg* 1998; 85: 1058–1060.
- 19 Belli G, Gayet B, Han HS, Wakabayashi G, Kim KH, Cannon R *et al.* Laparoscopic left hemihepatectomy a consideration for acceptance as standard of care. *Surg Endosc* 2013; 27: 2721–2726.
- 20 Cauchy F, Aussilhou B, Dokmak S, Fuks D, Gaujoux S, Farges O *et al*. Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. *Ann Surg* 2012; 256: 746–754.
- 21 Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D *et al*. The '50-50 criteria' on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. *Ann Surg* 2005; **242**: 824–828.
- 22 Ishizawa T, Hasegawa K, Kokudo N, Sano K, Imamura H, Beck Y *et al.* Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma. *Arch Surg* 2009; **144**: 46–51.
- 23 Rahbari NN, Garden OJ, Padbury R, Maddern G, Koch M, Hugh TJ *et al.* Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). *HPB (Oxford)* 2011; 13: 528–535.
- 24 Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L *et al*. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. *Surgery* 2011; **149**: 680–688.
- 25 Bedossa P. Presentation of a grid for computer analysis for compilation of histopathologic lesions in chronic viral

hepatitis C. Cooperative study of the METAVIR group. *Ann Pathol* 1993; **13**: 260–265.

795

- 26 Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004; 240: 205–213.
- 27 Lemeshow S, Hosmer DWJr. A review of goodness of fit statistics for use in the development of logistic regression models. *Am J Epidemiol* 1982; **115**: 92–106.
- 28 Soubrane O, Cherqui D, Scatton O, Stenard F, Bernard D, Branchereau S *et al*. Laparoscopic left lateral sectionectomy in living donors: safety and reproducibility of the technique in a single center. *Ann Surg* 2006; 244: 815–820.
- 29 Gonzalez R, Smith CD, Mason E, Duncan T, Wilson R, Miller J et al. Consequences of conversion in laparoscopic colorectal surgery. *Dis Colon Rectum* 2006; 49: 197–204.
- 30 Tranchart H, Gaillard M, Chirica M, Ferretti S, Perlemuter G, Naveau S. Multivariate analysis of risk factors for postoperative complications after laparoscopic liver resection. *Surg Endosc* 2014; [Epub ahead of print].
- 31 Nitta H, Sasaki A, Fujita T, Itabashi H, Hoshikawa K, Takahara T *et al*. Laparoscopy-assisted major liver resections employing a hanging technique: the original procedure. *Ann Surg* 2010; **251**: 450–453.
- 32 Kim SH, Cho SY, Lee KW, Park SJ, Han SS. Upper midline incision for living donor right hepatectomy. *Liver Transpl* 2009; 15: 193–198.
- 33 Demirbas T, Bulutcu F, Dayangac M, Yaprak O, Guler N, Oklu L et al. Which incision is better for living-donor right hepatectomy? Midline, J-shaped, or Mercedes. *Transplant Proc* 2013; 45: 218–221.
- 34 Eiriksson K, Fors D, Rubertsson S, Arvidsson D. High intra-abdominal pressure during experimental laparoscopic liver resection reduces bleeding but increases the risk of gas embolism. *Br J Surg* 2011; 98: 845–852.
- 35 Casillas S, Delaney CP, Senagore AJ, Brady K, Fazio VW. Does conversion of a laparoscopic colectomy adversely affect patient outcome? *Dis Colon Rectum* 2004; 47: 1680–1685.

Supporting information

Additional supporting information may be found in the online version of this article:

Fig. S1 Flow chart for the study (TIFF file)

 Table S1 Details of preoperative, operative and postoperative characteristics of patients who underwent conversion

 (Word document)

 Table S2 Univariable and multivariable analyses of the risk factors for postoperative complications (Word document)

Table S3 Comparison of the preoperative and operative characteristics of patients who underwent conversion and patients who had planned laparotomy (Word document)